Genesis Global Group
Genesis Drug Discovery & Development
GD3

You will now be redirected to the GD3 website

Genesis Drug Discovery & Development is a proud member of Genesis Drug Discovery & Development (GD3), a fully integrated CRO providing services to support drug discovery programs of our clients from target discovery through IND filing and managing Phase I-III clinical trials.

Learn more about GD3
Search

Disease Modeling

In Vitro Assays

GD3 offers a comprehensive suite of in vitro assays that serve as a basis for preclinical assessment of novel therapeutic agents in oncology, immune-oncology, neurodegenerative disorders and other indications. These assays are established on a vast collection of human and murine cell lines, including proprietary primary cell lines originating from our patient-derived PDX models. The data generated in our in vitro assays provides critical information on investigational agents’ effects on viability and cytotoxicity, cell cycle progression and programmed cell death. Using this data, our clients can advance their therapeutic programs toward In vivo animal model selection and subsequent clinical investigations.

  • Cytotoxicity

    GD3 has extensive experience in performing viability and cytotoxicity assays. We offer comprehensive cytotoxicity analysis of monotherapies and combination treatments with approved chemotherapies targeted and immunotherapeutic drugs to determine potential synergistic, additive or antagonistic effects.

  • Cell Cycle

    Whether you are exploring the mitotic pathway or evaluating novel compounds for cancer therapies, you can benefit from GD3‘s optimized cell cycle workflow and platform for cell cycle analysis leveraging advanced flow cytometry assays. Based on an established method of whole-cell staining, our cell cycle protocols can be used for rapid quantification of G0/G1, S, and G2/M phase cell cycle percentages to characterize or screen compounds.

  • Apoptosis

    Programmed cell death or apoptosis is closely coupled to several physiological and pathological processes, such as cancer, inflammation, immunological and neurodegenerative diseases. Changes in apoptotic pathways are a fundamental component of cancer research and are critical for understanding oncogenic mechanisms or evaluating new therapeutic interventions. The GD3 flow cytometry assays are simple, sensitive, and easy-to-perform tests for the quantitative detection of apoptosis in cell populations.